Dan Browne

Dan Browne has more than 30 years of entrepreneurial and executive leadership experience in the healthcare industry. He has led the development of multiple innovative products that are leaders in their category, as well as critical business development and partnership activities. He is the co-founder and former president and chief executive officer of Revance Therapeutics, Inc. Dan brought the company from early-stage incubator in 2002 to a highly successful IPO in 2014. During the course of his tenure, he led clinical, regulatory/quality, finance and commercial operations. Prior roles include president and CEO of Neomend, president and CEO of Prograft Medical, and business leader at WL Gore & Associates, Inc. Since 2020, Dan has been a board member to AVAVA Medical and Rythera Therapeutics. Dan holds an MBA from Pepperdine Graziadio Business School and studied cell biology at the University of Hawaii.